Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666730 · ClinicalTrials.gov registry record · Phase 2
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT01666730 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT01666730, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer. Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving metformin hydrochloride together with combination chemotherapy may kill more tumor cells
Interventions
- OTHER laboratory biomarker analysis
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG metformin hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-02-21 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666730
The ClinicalTrials.gov registry entry for NCT01666730 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01666730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01666730 about?
NCT01666730 is a clinical study titled "Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer". This phase II trial studies how well metformin hydrochloride, leucovorin calcium, fluorouracil, and oxaliplatin work in treating patients with metastatic pancreatic cancer. Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used i...
What is the current status of trial NCT01666730?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2013-02-21. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT01666730?
The interventions under investigation include: laboratory biomarker analysis (OTHER), oxaliplatin (DRUG), fluorouracil (DRUG), leucovorin calcium (DRUG), metformin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01666730?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.